Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

Genome Research

Volumn 15, Issue 7, 2005, Pages 928-935

  Loots, Gabriela G ^a,d   Kneissel, Michaela ^b   Keller, Hansjoerg ^b   Baptist, Myma ^b   Chang, Jessie ^a,d   Collette, Nicole M ^d   Ovcharenko, Dmitriy ^a   Plajzer Frick, Ingrid ^a   Rubin, Edward M ^a,c  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DOE JOINT GENOME INSTITUTE   (United States)

^d LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; SCLEROSTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE DYSPLASIA; BONE METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; ENHANCER REGION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC RECOMBINATION; LIMB DEVELOPMENT; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSGENICS; VAN BUCHEM DISEASE;

ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; ENHANCER ELEMENTS (GENETICS); GENE DELETION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC MARKERS; HUMANS; HYPEROSTOSIS; LINKAGE (GENETICS); MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; RATS; SEQUENCE ALIGNMENT; TUMOR CELLS, CULTURED; UNTRANSLATED REGIONS;

EID: 22244474640     PISSN: 10889051     EISSN: None     Source Type: Journal    
DOI: 10.1101/gr.3437105     Document Type: Article

References (35)

1. Balemans, W., Van Den Ende, J., Freire Paes-Alves, A., Dikkers, F.G., Willems, P.J., Vanhoenacker, F., de Almeida-Melo, N., Alves, C.F., Stratakis, C.A., Hill, S.C., et al. 1999. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am. J. Hum. Genet. 64: 1661-1669.
2. Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuyts, W., Van Den Ende, J., Willems, P., et al. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10: 537-543.
3. Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F.G., Hildering, P., Willems, P.J., et al. 2002. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39: 91-97.
4. Beighton, P., Davidson, J., Durr, L., and Hamersma, H. 1977. Sclerosteosis-An autosomal recessive disorder. Clin. Genet. 11: 1-7.
5. Brunet, L.J., McMahon, J.A., McMahon, A.P., and Harland, R.M. 1998. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457.
6. Brunkow, M.E., Gardner, J.C., Van Ness, J., Paeper, B.W., Kovacevich, B.R., Proll, S., Skonier, J.E., Zhao, L., Sabo, P.J., Fu, Y., et al. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68: 577-589.
7. Chuzhanova, N., Abeysinghe, S.S., Krawczak, M., and Cooper, D.N. 2003. Translocation and gross deletion breakpoints in human inherited disease and cancer II: Potential involvement of repetitive sequence elements in secondary structure formation between DNA ends. Hum. Mutat. 22: 245-251.
8. Cimbora, D.M., Schubeler, D., Reik, A., Hamilton, J., Francastel, C., Epner, E.M., and Groudine, M. 2000. Long-distance control of origin choice and replication timing in the human β-globin locus are independent of the locus control region. Mol. Cell. Biol. 20: 5581-5591.
9. Curtin, P.T. and Kan, Y.W. 1988. The inactive β globin gene on a γ δ β thalassemia chromosome has a normal structure and functions normally in vitro. Blood 71: 766-770.
10. Curtin, P., Pirastu, M., Kan, Y.W., Gobert-Jones, J.A., Stephens, A.D., and Lehmann, H. 1985. A distant gene deletion affects β-globin gene function in an atypical γ δ β-thalassemia. J. Clin. Invest. 76: 1554-1558.
11. Devlin, R.D., Du, Z., Pereira, R.C., Kimble, R.B., Economides, A.N., Jorgetti, V., and Canalis, E. 2003. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144: 1972-1978.
12. Enattah, N.S., Sahi, T., Savilahti, E., Terwilliger, J.D., Peltonen, L., and Jarvela, I. 2002. Identification of a variant associated with adult-type hypolactasia. Nat. Genet. 30: 233-237.
13. Hamersma, H., Gardner, J., and Beighton, P. 2003. The natural history of sclerosteosis. Clin. Genet. 63: 192-197.
14. Ionasescu, V.V., Searby, C., Ionasescu, R., Neuhaus, I.M., and Werner, R. 1996. Mutations of the noncoding region of the connexin32 gene in X-linked dominant Charcot-Marie-Tooth neuropathy. Neurology 47: 541-544.
15. Khokha, M.K., Hsu, D., Brunet, L.J., Dionne, M.S., and Harland, R.M. 2003. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat. Genet. 34: 303-307.
16. Kleinjan, D.A., Seawright, A., Schedl, A., Quinlan, R.A., Danes, S., and van Heyningen, V. 2001. Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6. Hum. Mol. Genet. 10: 2049-2059.
17. Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L., Swing, D.A., Court, D.L., Jenkins, N.A., and Copeland, N.G. 2001. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73: 56-65.
18. Lettice, L.A., Heaney, S.J., Purdie, L.A., Li, L., de Beer, P., Oostra, B.A., Goode, D., Elgar, G., Hill, R.E., and de Graaff, E. 2003. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum. Mol. Genet. 12: 1725-1735.
19. Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S.E., and Wu, D. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280: 19883-19887.
20. Mankoo, B.S., Skuntz, S., Harrigan, I., Grigorieva, E., Candia, A., Wright, C.V., Arnheiter, H., and Pachnis, V. 2003. The concerted action of Meox homeobox genes is required upstream of genetic pathways essential for the formation, patterning and differentiation of somites. Development 130: 4655-4664.
21. Mortlock, D.P., Guenther, C., and Kingsley, D.M. 2003. A general approach for identifying distant regulatory elements applied to the Gdf6 gene. Genome Res. 13: 2069-2081.
22. Nobrega, M.A., Ovcharenko, I., Afzal, V., and Rubin, E.M. 2003. Scanning human gene deserts for long-range enhancers. Science 302: 413.
23. Ovcharenko, I., Loots, G.G., Hardison, R.C., Miller, W., and Stubbs, L. 2004. zPicture: Dynamic alignment and visualization tool for analyzing conservation profiles. Genome Res. 14: 472-477.
24. Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M., and Recker, R.R. 1987. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2: 595-610.
25. Petropoulos, H., Gianakopoulos, P.J., Ridgeway, A.G., and Skerjanc, I.S. 2004. Disruption of Meox or Gli activity ablates skeletal myogenesis in P19 cells. J. Biol. Chem. 279: 23874-23881.
26. Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lundin, P., Maner, S., Massa, H., Walker, M., Chi, M., et al. 2004. Large-scale copy number polymorphism in the human genome. Science 305: 525-528.
27. Staehling-Hampton, K., Proll, S., Paeper, B.W., Zhao, L., Charmley, P., Brown, A., Gardner, J.C., Galas, D., Schatzman, R.C., Beighton, P., et al. 2002. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110: 144-152.
28. Tsui, F.W., Tsui, H.W., Cheng, E.Y., Stone, M., Payne, U., Reveille, J.D., Shulman, M.J., Paterson, A.D., and Inman, R.D. 2003. Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum. 48: 791-797.
29. Uitterlinden, A.G., Arp, P.P., Paeper, B.W., Charmley, P., Proll, S., Rivadeneira, F., Fang, Y., van Meurs, J.B., Britschgi, T.B., Latham, J.A., et al. 2004. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am. J. Hum. Genet. 75: 1032-1045.
30. Van Bezooijen, R.L., Roelen, B.A., Visser, A., Van Der Wee-Pals, L., De Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S.E., Ten Dijke, P., and Lowik, C.W. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199: 805-814.
31. Van Hul, W., Balemans, W., Van Hul, E., Dikkers, F.G., Obee, H., Stokroos, R.J., Hildering, P., Vanhoenacker, F., Van Camp, G., and Willems, P.J. 1998. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am. J. Hum. Genet. 62: 391-399.
32. Van Hul, W., Vanhoenacker, F., Balemans, W., Janssens, K., and De Schepper, A.M. 2001. Molecular and radiological diagnosis of sclerosing bone dysplasias. Eur. J. Radiol. 40: 198-207.
33. Wang, H.L., Wu, T., Chang, W.T., Li, A.H., Chen, M.S., Wu, C.Y., and Fang, W. 2000. Point mutation associated with X-linked dominant Charcot-Marie-Tooth disease impairs the P2 promoter activity of human connexin-32 gene. Brain Res. Mol. Brain Res. 78: 146-153.
34. Wergedal, J.E., Veskovic, K., Hellan, M., Nyght, C., Balemans, W., Libanati, C., Vanhoenacker, F.M., Tan, J., Baylink, D.J., and Van Hul, W. 2003. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J. Clin. Endocrinol. Metab. 88: 5778-5783.
35. Winkler, D.G., Sutherland, M.K., Geoghegan, J.C., Yu, C., Hayes, T., Skonier, J.E., Shpektor, D., Jonas, M., Kovacevich, B.R., Staehling-Hampton, K., et al. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22: 6267-6276.